Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: musculoskeletal disease

Dealing with Simultaneous Cancer & Rheumatic Disease

Thomas R. Collins  |  March 17, 2018

SAN DIEGO—New insights into how scleroderma and myositis may be linked with cancer have led to intriguing questions that could impact patient care, experts said at the 2017 ACR/ARHP Annual Meeting in November. Understanding the relationship between cancer and rheumatic diseases is important because rheumatologists are seeing more and more patients with both diseases, and…

Filed under:Meeting ReportsSystemic Sclerosis Tagged with:ACR/ARHP Annual Meeting

Lacrimal & Tear Fluid Yield Clues to Dry Eye Disease

Lara C. Pullen, PhD  |  December 4, 2017

A recent study suggests novel markers of dry eye disease can be found in the lacrimal fluid and tear fluid of patients. Researchers analyzed the proteins in these fluids and found immune response-related proteins are upregulated at the protein level in lacrimal fluid of patients with dry eye disease and may be an important biomarker…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Dry eyeeyeEye diseasetear fluid

Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease

Veronika Sharp, MD, Alice Chuang, MD, Lily Kao, MD, RMSK, & Midori Jane Nishio, MD, RhMSUS  |  November 9, 2017

A 57-year-old Ghanaian woman was referred to our rheumatology practice with acute, left elbow swelling and pain. The referring oncologist suspected gout, because the patient had hyperuricemia. Six months before, the patient was diagnosed with stage IV human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell lymphoma (ATLL). Her initial oncologic manifestations included multiple thoracic,…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportClinicalDiagnosisGouthyperuricemiamalignantoutcomepatient careRheumatic DiseaserheumatologyT cell lymphomaUltrasound

The ACR Gears Up for Rheumatic Disease Awareness Month in September

From the College  |  July 13, 2017

Awareness can be an ambiguous term, but it makes all the difference in rheumatology. The first weeks and months following the onset of rheumatic disease symptoms are known as the window of opportunity. Prompt treatment can prevent damage to joints and other organs, improve long-term function and increase the likelihood of achieving disease remission. But…

Filed under:From the College Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)AwarenessEducationPittsburgh Steelerspublic healthRheumatic DiseaseTerry Bradshaw

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

Kurt Ullman  |  June 15, 2017

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a…

Filed under:ConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:BiologicsClinicaldrug therapyfatigueguidelineinflammatory musculoskeletal diseasePainpatient carerecommendationRheumatic DiseaseSjogren'sTreatment

Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

Mary Beth Nierengarten  |  April 20, 2017

WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

Filed under:ConditionsMeeting ReportsResearch RheumSystemic Lupus Erythematosus Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)BiomarkersCardiovascular diseasegeneticLupuspatient careResearchrheumatologyriskSLEvariant

Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

Arthritis Care & Research  |  April 2, 2017

The clinical practice guidelines for managing Sjögren’s syndrome, developed by the Sjögren’s Syndrome Foundation with the ACR, were designed to improve quality and consistency of care. In total, 19 recommendations were agreed on, which include managing the rheumatic and systemic aspects of the disease. Recommendations include a decision tree for the use of DMARDs for inflammatory musculoskeletal pain, use of self-care measures and exercise to reduce fatigue, and the use of rituximab in selected clinical settings for oral and ocular dryness…

Filed under:ConditionsResearch RheumSjögren’s Disease Tagged with:Arthritis Care & ResearchClinical Practice GuidelinesfatigueMusculoskeletalrituximabsiccaSjogren's

Oksana Kuzmina/shutterstock.comx

Environmental Factors in Pediatric Systemic Autoimmune Diseases

Lisa G. Rider, MD, & Frederick W. Miller, MD, PhD  |  March 20, 2017

Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

Filed under:Conditions Tagged with:air pollutionAutoimmune diseaseenvironmental factorgeneticInfectionJuvenile idiopathic arthritisKawasaki diseasepatient carePediatricsRheumatic DiseaserheumatologistriskSmoking

What Rheumatologists Wish Their Colleagues Knew: Managing Skin Disease & Comorbidities

Richard Quinn  |  March 3, 2017

From treating rashes to uncovering a case of osteoarthritis, dermatologists and rheumatologists can work together in a variety of ways to improve patient care, says Joseph F. Merola, MD, MMSc…

Filed under:ConditionsPsoriatic ArthritisSystemic Sclerosis Tagged with:DermatologyPsoriasisPsoriatic Arthritisrheumatologistskinskin disease

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  February 16, 2017

Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-interleukincase reportClinicalDiagnosisDiseaseErdheim-ChesterinflammatoryinterferonPathogenesistherapyTreatment

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 93
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences